HC Wainwright & Co. Reiterates Buy on Cullinan Oncology, Maintains $50 Price Target
HC Wainwright & Co. analyst Edward White reiterates Cullinan Oncology (NASDAQ:CGEM) with a Buy and maintains $50 price target.
Cullinan Oncology Licenses U.S. Rights To The First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator From Harbour BioMed; Currently In A Phase 1 Clinical Study Being Conducted At U.s. And Australian Sites In Patients With Advanced Solid Tumors
Cullinan Oncology, Inc. (NASDAQ:CGEM) and Harbour BioMed (HKEX: 02142) today announced that Cullinan Oncology has entered into an exclusive license with Harbour BioMed for the development and
5 Value Stocks In The Healthcare Sector
What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of…
5 Value Stocks To Watch In The Healthcare Sector
What is a Value Stock? A value stock traditionally has a lower price when compared to stock prices…
BTIG Initiates Coverage On Cullinan Oncology with Buy Rating, Announces Price Target of $20
BTIG analyst Kaveri Pohlman initiates coverage on Cullinan Oncology (NASDAQ:CGEM) with a Buy rating and announces Price Target of $20.
A Look Into Healthcare Sector Value Stocks
The Meaning Behind Value Stocks
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
Cullinan Management Q2 EPS $3.77 Up From $(0.27) YoY
Cullinan Management (NASDAQ:CGEM) reported quarterly earnings of $3.77 per share. This is a 1496.3 percent increase over losses of $(0.27) per share from the same period last year.
Short Volatility Alert: Cullinan Oncology
On Monday, shares of Cullinan Oncology, Inc. (NASDAQ: CGEM) experienced volatile short activity. After the activity, the stock price went up at 2.45% to $10.88.
The overall sentiment for CGEM has been Bullish.
90 Biggest Movers From Yesterday
Gainers
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) surged 70.5% to close at $0.1330 on Thursday after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered direct offering.
Mid-Afternoon Market Update: Nasdaq Down 200 Points; Dutch Bros Shares Plunge
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping more than 200 points on Thursday.